|
**Overview**: Kappa Lambda Free Light Chain Serum Panel**Introduction**: The Kappa Lambda Free Light Chain Serum Panel is a diagnostic tool designed to assess free light chains using serum samples. In India, multiple myeloma affects ~10,000-15,000 new cases/year, with serum free light chains (sFLC) more sensitive than electrophoresis for detecting light-chain-only myeloma (~20 percent of cases) and monitoring minimal residual disease. High morbidity from under-testing in rural/low-SES patients with bone pain, anemia, renal failure, limited labs, delayed bortezomib-based therapy leading to end-organ damage. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs immunoassay for kappa and lambda free light chains and kappa/lambda ratio over 1-2 days with high accuracy, valuable for diagnosis and monitoring. This diagnostic falls under protein screening and targets patients with suspected plasma cell dyscrasia or monoclonal gammopathy, addressing accurate detection to guide bone marrow biopsy or chemotherapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise light chain assessment and improving myeloma outcomes. Its serum-based approach ensures reliable quantification.**Other Names**: Kappa Lambda S Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: sFLC assay standard; in India, routine in myeloma workup.**Purpose**: The test assesses 3 parameters including kappa free light chain to guide multiple myeloma screening, detect abnormal ratio, inform monitoring.**Test Parameters**: 1. Kappa Free Light Chain, 2. Lambda Free Light Chain, 3. Kappa/Lambda Ratio.**Pretest Condition**: No fasting required; patients should report bone pain or renal issues.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on anemia, renal function, bone pain.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed myeloma including organ damage, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or renal impairment can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal kappa/lambda ratio indicates monoclonal expansion, necessitating specialist input.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: SPEP, bone marrow biopsy for confirmation.**Test Limitations**: Renal function affects levels; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Myeloma Studies India 2023. |
